New Treatment Shows Promise for ALS Symptoms in SCA2

Study Overview

A recent study published in the journal Nature has identified a potential treatment to reverse symptoms of amyotrophic lateral sclerosis (ALS) in a related condition known as spinocerebellar ataxia type 2 (SCA2). Researchers conducted experiments using a mouse model that replicated the disease, administering injections of a specific oligonucleotide called ASO7. Following the treatment, the mice demonstrated improved motor performance.

Understanding Neurodegenerative Diseases

Parkinson’s disease and ALS, commonly referred to as Lou Gehrig’s disease, are two well-known neurodegenerative disorders. While they exhibit similar symptoms and share a genetic component, their underlying causes differ significantly. Parkinson’s disease is classified as autosomal dominant, indicating it is hereditary, whereas ALS arises from mutations and is not inherited. SCA2 is another neurodegenerative disorder that closely resembles both Parkinson’s and ALS, often presenting similar symptoms. Like Parkinson’s, SCA2 is autosomal dominant and typically manifests later in life, with its pathology linked to the expansion of DNA segments associated with the ATXN2 protein.

Research Findings

In the study led by researchers from the University of Utah, the University of California Los Angeles, and Ionis Pharmaceuticals, the focus was on RNA-targeted therapies for SCA2. The research team utilized genetically modified mice that exhibited progressive, adult-onset neuronal degeneration reflective of the clinical characteristics observed in humans with SCA2. A bacterial-artificial-chromosome transgene facilitated the expression of the human ATXN2 gene across various brain regions and the spinal cord, effectively mimicking SCA2 symptoms.

The experimental group of mice received ASO7 injections coinciding with the onset of motor performance decline. Remarkably, ten weeks post-treatment, the mice that received ASO7 showcased enhanced motor performance when compared to the control group, which received saline injections. These findings suggest that antisense oligonucleotides (ASOs) could serve as a viable treatment option for human neurodegenerative diseases.

Implications for Future Treatments

Currently, autosomal dominant neurodegenerative diseases, such as SCA2 and Parkinson’s, lack effective cures and present significant treatment challenges. This study marks a pioneering effort in directly targeting the genes responsible for these diseases. The encouraging results pave the way for exploring new therapeutic avenues for neurodegenerative disorders and could ultimately lead to the development of innovative treatments for SCA2 and ALS in humans.

Conclusion

The research highlights a significant breakthrough in the quest for effective therapies for neurodegenerative diseases, emphasizing the potential of RNA-targeted approaches in addressing these complex conditions.

Written By: Brian Jones